| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | SR1001 | CTRPv2 | pan-cancer | AAC | -0.024 | 0.5 |
| mRNA | ruxolitinib | GDSC1000 | pan-cancer | AAC | 0.02 | 0.5 |
| mRNA | BRD-K90370028 | CTRPv2 | pan-cancer | AAC | 0.034 | 0.5 |
| mRNA | CHM-1 | CTRPv2 | pan-cancer | AAC | 0.02 | 0.5 |
| mRNA | Erlotinib | FIMM | pan-cancer | AAC | 0.1 | 0.5 |
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | 0.029 | 0.5 |
| mRNA | PRIMA-1-Met | CTRPv2 | pan-cancer | AAC | -0.032 | 0.5 |
| mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | -0.023 | 0.5 |
| mRNA | HG-6-64-1 | GDSC1000 | pan-cancer | AAC | 0.02 | 0.5 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | 0.028 | 0.5 |